Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Receivables (2016 - 2025)

Agios Pharmaceuticals' Change in Receivables history spans 8 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 459.84% year-over-year to $5.5 million; the TTM value through Dec 2025 reached $6.5 million, up 397.92%, while the annual FY2025 figure was $6.5 million, 397.92% up from the prior year.
  • Change in Receivables reached $5.5 million in Q4 2025 per AGIO's latest filing, up from $43000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $8.1 million in Q2 2021 to a low of -$7.0 million in Q4 2021.
  • Average Change in Receivables over 5 years is $556684.2, with a median of $473000.0 recorded in 2023.
  • The largest YoY upside for Change in Receivables was 459.84% in 2025 against a maximum downside of 218.97% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$7.0 million in 2021, then soared by 140.2% to $2.8 million in 2022, then plummeted by 41.85% to $1.6 million in 2023, then plummeted by 39.35% to $991000.0 in 2024, then surged by 459.84% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Change in Receivables are $5.5 million (Q4 2025), $43000.0 (Q3 2025), and $1.6 million (Q2 2025).